A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2021-04-20
Target enrollment:
Participant gender:
Summary
This is a research study to be done at multiple sites in participants with advanced acute
myeloid leukemia (AML) that have a mutation in Fms-like tyrosine kinase-3 internal tandem
duplications (FLT3-ITD). This study is to learn more about an investigational drug,
quizartinib, being tested with the anti-cancer medicine CPX-351 (also called Vyxeos™), which
is approved and widely used to treat AML.
The purpose of this study is to assess the safety, tolerability and survival of patients
receiving the combination of CPX-351 and quizartinib.